Using 68Ga-DOTATATE PET/CT to diagnose soft tissue sarcomas
Official title: Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy
Run by Ohio State University Comprehensive Cancer Center · NCT06500065 · Data updated 2026-11-12
This study is testing a new type of imaging called 68Ga-DOTATATE PET/CT to see if it can help doctors better diagnose soft tissue sarcomas in patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | September 30, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT06500065 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with any stage of soft tissue sarcomas who are candidates for systemic therapies.
✕Probably not a fit
Patients with hypersensitivity to somatostatin, those who have received long-acting somatostatin analogs recently, or those unable to undergo the imaging due to claustrophobia or other medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the effectiveness of 68Ga-DOTATATE digital PET/CT imaging in diagnosing soft tissue sarcomas. The study aims to assess the feasibility and capability of this advanced imaging technique, which may enhance image quality and provide better detection of tumors. Patients will receive the radiotracer intravenously and undergo imaging to evaluate tumor characteristics and response to therapy. The trial also seeks to determine the safety of 68Ga-DOTATATE in this patient population.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment planning for patients with soft tissue sarcomas.
How similar studies have gone: While this specific approach is novel, similar imaging techniques have shown promise in enhancing diagnostic capabilities for various cancers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>= 18 years of age * Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies * Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities. Exclusion Criteria: * Hypersensitivity to somatostatin or similar peptides * Somatostatin long-acting analog in the past 6 months * Patients who are pregnant or lactating * Patients who are currently incarcerated * Patients with acute infections * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)
Where it's running
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: Gabriel R Tinoco Suarez — Ohio State University Comprehensive Cancer Center
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
-
Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma
This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.